T-Lymphocyte Response in Renal Cell Carcinoma

  • Kyogo Itoh
  • Lazel B. Augustus
  • Masanobu Nakao
  • Jiro Miyajima
  • Omar Eton
  • David A. Swamson
Conference paper

Abstract

Several important immunological properties of tumor-infiltrating lymphocytes (TIL) from renal cell carcinoma (RCC) have been reported: (a) the magnitude of lymphocyte infiltration in RCC was higher than that in the other cancers (1); (b) the autologous tumor cell lysis in IL-2-activated TIL from RCC was higher than that in the other cancers except metastatic melanoma (1–4); (c) non-T cells, including CD3-CD56 + or CD3-CD16+ natural killer cells, were primarily responsible for autologous tumor cell lysis (1–5); (d) T cells were enriched with memory T cell markers (6); and (e) IL-2-activated TIL showed oligoclonal expansion (7–9). Therefore, TIL in RCC appeared to be more involved in host tumor-interaction than PBMC. However, there are few findings, to our knowledge, supporting the idea that RCC-specific T cells exist in TIL, PBMC, or the other immune organs in RCC patients. (10) Neither RCC TIL nor PBMC cultured with IL-2 alone displayed tumor-specific cytotoxicity. (1–8) These results suggest that RCC TIL have little or no CTL precursors, possibly because of the lower immunogeneity of untreated RCC cells. Poorly immunogenic animal tumor cells can be converted into highly immunogenic tumors by several techniques: (a) viral infection of tumor cells (11,12), (b) treatment of tumor cells with mutagenic agents such as 1-methyl-3-nitro-l-nitrosoguanidine (13, 14), (c) treatment of tumor cells with ultraviolet-B (UV) radiation or the others (15–19), (d) transfection of tumor cells with MHC class I antigens (20,21), and (e) transfection of tumor cells with cytokine genes (22, 23).

Keywords

Leukemia Influenza Oncol Noma Triazenes 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Balch CM, Riley LB, Bae Y-J, Salmeron MA, Platsoucas CD, von Eschenbach AC, Itoh K (1990) Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 125:200–205.PubMedGoogle Scholar
  2. 2.
    Alexander J, Rayman P, Edinger M, Connelly R, Tubbs R, Bukowski R, Pontes E, Finke J (1990) TIL from renal cell carcinoma: restimulation with tumor influences proliferation and cytotoxic activity. Int J Cancer 45:119–124.PubMedCrossRefGoogle Scholar
  3. 3.
    Belldegrun A, Muul LM, Rosenberg SA (1988) Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell carcinoma: Isolation, characterization, and antitumor activity. Cancer Res 47: 206–214.Google Scholar
  4. 4.
    Finke JH, Rayman P, Alexander J, Edinger M, Tubbs RR, Connelly R, Pontes E, Bukowski R (1990) Characterization of the cytotoxic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res 50:2363–2370.PubMedGoogle Scholar
  5. 5.
    Hayakawa K, Salmeron MA, Parkinson DR, Markowitz AB, von Eschenbach AC, Legha SS, Balch CM, Ross MI, Augustus LB, Itoh K (1991) Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma. Journal of Immunology 10: 313–325.Google Scholar
  6. 6.
    Alexander J, Edinger M, Connelly R, Tubbs R, Pontes E, Bukowski R, Finke J (1990) Isolation of activated CD8+ cells from PBL and tumor-infiltrating lymphocytes (TIL) from renal cell carcinoma (RCC) and their characterization. FASEB J 4:A2021.Google Scholar
  7. 7.
    Belldegrun A, Kasid A, Uppenkamp M, Topalian SL, Rosenberg SA (1989) Human tumor-infiltrating lymphocytes.Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. J Immunol 142:4520–45268.PubMedGoogle Scholar
  8. 8.
    Fishleder AJ, Finke JH, Tubbs R, Bukowski RM, (1990) Inductionby interleukin2 if oligoclonal expansion of cultured tumor-infiltrating lymphocytes. J Natl. Cancer Inst 82:124–128.PubMedCrossRefGoogle Scholar
  9. 9.
    Morita T, Salmeron MA, Hayakawa K, Swanson DA, von Eshencach AC, Itoh K (1992) T cell functions of interleukin-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma. Immunology 4:225–235.Google Scholar
  10. 10.
    Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M,RegionalHofstetter A, Riethmuller G, Segurado OG (1993) Tumor-Specific Lysis of Human Renal Cell Carcinoma by Tumor-Infiltrating Lymphocytes. J.Immunol. 151: 4209–4220.Google Scholar
  11. 11.
    Boone C, Blackman K (1972) Augmented immunogenicity of tumor cell homogenates infected with influenza virus. Cancer Res 32:1018–1022.PubMedGoogle Scholar
  12. 12.
    Kobayashi H, Sendo F, Shirai T, Kaji H, Kodama T (1969)Modification in growthof transplantable rat tumors exposed tofriend virus J Natl. Cancer Int 42:413–418.Google Scholar
  13. 13.
    Uyttenhove C, Van Sniek J, Boon T (1980) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. J. Exp Med 152: 1175–1183.PubMedCrossRefGoogle Scholar
  14. 14.
    Van Pel A, Vessiere F, Boon T (1983) Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis. J Exp Med 457:1992–2001.Google Scholar
  15. 15.
    Hostetler LW, Kripke ML (1987) Origin and significance of transplantation antigens induced on cells transformed by UV radiation: In: Greene MI, Hamaoka T(eds), Development recognition of the transformed cells. Plenum, New York, pp 307–329.Google Scholar
  16. 16.
    Hostetler LW, Kripke (1988) Proportion of antigenic variants induced by in vitro UV irradiation differs in clones derived from a single tumor. J Immunol 140:666–670.PubMedGoogle Scholar
  17. 17.
    Contessa AR, Bonmasser A, Giampietri A, Circolo A, Goldin A, Fioretti MC(1981) In vitro generation of a highly immunogenic sublime of L1210 leukemia following exposure to 5-(3’-dimethyl-tri-azeno) imidazol-4-carboxamide.Cancer Res 41:2476–2482.PubMedGoogle Scholar
  18. 18.
    Frost P, Kerbel RS, Bauer E, Tartamella-Biondo R, Cefalu W (1983) Mutagen treatment as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors. Cancer Res 43:125–132.PubMedGoogle Scholar
  19. 19.
    Schmid FA, Hutchison DJ (1973) Decrease in oncogenic potential of L1210 leukemia by triazenes. Cancer Res 33:2161–2165.PubMedGoogle Scholar
  20. 20.
    Hui K, Grosveld F, Festenstein H (1985) Rejection of transplantable AKR leukemia cellsfollowing MHC DNA-mediated cell transformation. Nature 311:750–752.CrossRefGoogle Scholar
  21. 21.
    Weber JS, Jay G, Tanaka K, Rosenberg RA (1987) Immunotherapy of a murine tumor with interleukin 2.-Increased sensitivity after MHC Class I gene transfection. J Exp Med 166: 1716–1733.PubMedCrossRefGoogle Scholar
  22. 22.
    Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor response Journal Cell 60:397–403.Google Scholar
  23. 23.
    Tepper, R.I, Pattengale PK, Leder P (1989) Murine interleukin-4 displays potent antitumor activity in vivo. Cell 57:503–512.PubMedCrossRefGoogle Scholar
  24. 24.
    Harris OT, (1983) Hormonal Therapy and Chemotherapy of Renal Cell Carcinoma. Semin. Oncol. 10:422–430.Google Scholar
  25. 25.
    Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghansen SE, Matory YT, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin 2 or high-dose interleukin alone. N. Engl. J. Med. 316:889–897.PubMedCrossRefGoogle Scholar
  26. 26.
    Umezu Y, Augustus LB, Seito D, Hayakawa K, Ross MI Eton O, Swanson DA, Itoh K (1993) Increase in the ability of human cancer cells to induce cytotoxic T lymphocytes by ultraviolet irradiation. Cancer Immunol. Immunother. 37: 392–399.CrossRefGoogle Scholar
  27. 27.
    Hayakawa K, Monta T, Augustus LB, von Eschenbach AC, Itoh K (1992) Human renal cell carcinoma cells are able to activate natural killer cells. Int J Cancer 51:290–295.PubMedCrossRefGoogle Scholar
  28. 28.
    Itoh K, Umezu Y, Monta T, Saya H, Seito D, Augustus LB, Nakao M, Sakata M, Masuoka K, Matsui H (1994) Increase in capability of interleukin 2 genetransduced renal cell carcinoma cells to induce cytotoxic lymphocytes. Kurume Medical J. in press.Google Scholar
  29. 29.
    Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A, Tsunasawa S, Sakiyama F, Matsui H, Takahara Y, Taniguchi T, Kishimoto T (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to induce immunoglobulin. Nature 324: 73–76.PubMedCrossRefGoogle Scholar
  30. 30.
    Karasuyama H, Tohyama N, Tada T (1989) Autocrine growth and tumorigenicity of interleukin 2-dependent helper T cells transfected with IL2 gene. J. Exp. Med 169:13–25.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1995

Authors and Affiliations

  • Kyogo Itoh
    • 1
  • Lazel B. Augustus
    • 2
  • Masanobu Nakao
    • 1
  • Jiro Miyajima
    • 1
  • Omar Eton
    • 3
  • David A. Swamson
    • 4
  1. 1.Department of ImmunologyKurume University School of MedicineKurumeJapan
  2. 2.Department of ImmunologyUniversity of Texas, M.D. Anderson Cancer CenterHoustonUSA
  3. 3.Department of Medical OncologyUniversity of Texas, M.D.Anderson Cancer CenterHoustonUSA
  4. 4.Department of UrologyUniversity of Texas, M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations